JP2007176932A - Liquid preparation applied for mucosa - Google Patents
Liquid preparation applied for mucosa Download PDFInfo
- Publication number
- JP2007176932A JP2007176932A JP2006320940A JP2006320940A JP2007176932A JP 2007176932 A JP2007176932 A JP 2007176932A JP 2006320940 A JP2006320940 A JP 2006320940A JP 2006320940 A JP2006320940 A JP 2006320940A JP 2007176932 A JP2007176932 A JP 2007176932A
- Authority
- JP
- Japan
- Prior art keywords
- mucosa
- cation
- polyethylene glycol
- responsive polymer
- applied solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000007788 liquid Substances 0.000 title claims abstract description 17
- 210000004877 mucosa Anatomy 0.000 title claims abstract description 8
- 238000002360 preparation method Methods 0.000 title abstract description 23
- 229920000642 polymer Polymers 0.000 claims abstract description 23
- 229920001223 polyethylene glycol Polymers 0.000 claims abstract description 18
- 239000002202 Polyethylene glycol Substances 0.000 claims abstract description 14
- 229920002148 Gellan gum Polymers 0.000 claims abstract description 11
- 239000000216 gellan gum Substances 0.000 claims abstract description 11
- 235000010492 gellan gum Nutrition 0.000 claims abstract description 11
- 230000007423 decrease Effects 0.000 claims abstract description 8
- 238000002156 mixing Methods 0.000 claims abstract description 7
- 239000001814 pectin Substances 0.000 claims abstract description 6
- 229920001277 pectin Polymers 0.000 claims abstract description 6
- 235000010987 pectin Nutrition 0.000 claims abstract description 6
- 239000000243 solution Substances 0.000 claims description 30
- 150000001768 cations Chemical class 0.000 claims description 19
- 239000007923 nasal drop Substances 0.000 claims description 12
- 239000003889 eye drop Substances 0.000 claims description 10
- 239000003125 aqueous solvent Substances 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 238000013329 compounding Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 7
- 230000000694 effects Effects 0.000 abstract description 4
- 239000012736 aqueous medium Substances 0.000 abstract 1
- 230000000052 comparative effect Effects 0.000 description 11
- 239000000499 gel Substances 0.000 description 11
- 229940100662 nasal drops Drugs 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- 239000008213 purified water Substances 0.000 description 8
- 229940012356 eye drops Drugs 0.000 description 7
- 230000002378 acidificating effect Effects 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 230000007794 irritation Effects 0.000 description 4
- 229960003630 ketotifen fumarate Drugs 0.000 description 4
- YNQQEYBLVYAWNX-WLHGVMLRSA-N ketotifen fumarate Chemical compound OC(=O)\C=C\C(O)=O.C1CN(C)CCC1=C1C2=CC=CC=C2CC(=O)C2=C1C=CS2 YNQQEYBLVYAWNX-WLHGVMLRSA-N 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 210000004400 mucous membrane Anatomy 0.000 description 4
- 239000001509 sodium citrate Substances 0.000 description 4
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 4
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000000857 drug effect Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- XPFJYKARVSSRHE-UHFFFAOYSA-K trisodium;2-hydroxypropane-1,2,3-tricarboxylate;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound [Na+].[Na+].[Na+].OC(=O)CC(O)(C(O)=O)CC(O)=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O XPFJYKARVSSRHE-UHFFFAOYSA-K 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000002826 coolant Substances 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 208000014617 hemorrhoid Diseases 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- SGHZXLIDFTYFHQ-UHFFFAOYSA-L Brilliant Blue Chemical compound [Na+].[Na+].C=1C=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C(=CC=CC=2)S([O-])(=O)=O)C=CC=1N(CC)CC1=CC=CC(S([O-])(=O)=O)=C1 SGHZXLIDFTYFHQ-UHFFFAOYSA-L 0.000 description 1
- DBAKFASWICGISY-BTJKTKAUSA-N Chlorpheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 DBAKFASWICGISY-BTJKTKAUSA-N 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- DJDFFEBSKJCGHC-UHFFFAOYSA-N Naphazoline Chemical compound Cl.C=1C=CC2=CC=CC=C2C=1CC1=NCCN1 DJDFFEBSKJCGHC-UHFFFAOYSA-N 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 239000000043 antiallergic agent Substances 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003212 astringent agent Substances 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229940046978 chlorpheniramine maleate Drugs 0.000 description 1
- 230000002844 continuous effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000001879 gelation Methods 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 229960004760 naphazoline hydrochloride Drugs 0.000 description 1
- 239000002997 ophthalmic solution Substances 0.000 description 1
- 229940054534 ophthalmic solution Drugs 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 229940021790 tetrahydrozoline hydrochloride Drugs 0.000 description 1
- BJORNXNYWNIWEY-UHFFFAOYSA-N tetrahydrozoline hydrochloride Chemical compound Cl.N1CCN=C1C1C2=CC=CC=C2CCC1 BJORNXNYWNIWEY-UHFFFAOYSA-N 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
Images
Landscapes
- Medicinal Preparation (AREA)
Abstract
Description
本発明は粘膜適用液剤に関し、さらに詳しくはカチオン応答型高分子による付着性の経時的な低下を抑制もしくは軽減した粘膜適用液剤に関する。 The present invention relates to a mucosa-applied solution, and more particularly to a mucosa-applied solution in which a decrease in adhesion over time due to a cation-responsive polymer is suppressed or reduced.
一般的に点鼻剤、点眼剤などの薬剤は即効性があるため、対症療法的に用いられることが多い。しかし、滞留性が劣るため十分な持続効果が得られていなかった。このため、持続的な効果が得られる製剤が望まれていた。 In general, drugs such as nasal drops and eye drops are effective immediately and are often used for symptomatic treatment. However, since the retention was poor, a sufficient sustaining effect was not obtained. For this reason, the formulation which can obtain a lasting effect was desired.
ヒドロキシプロピルセルロースなどの増粘剤でゲル状にした製剤は、投与したときに薬物含有製剤が投与部位に付着し、薬効成分の利用率が上がるため持続した効果が期待できる。しかし、ゲル状の製剤は一般的な噴霧器で良好に噴霧できない等の欠点がある。したがって、塗布する前の製剤は液状で、塗布後にゲル化する製剤が好ましい。 A preparation made into a gel with a thickening agent such as hydroxypropylcellulose can be expected to have a sustained effect because the drug-containing preparation adheres to the administration site when administered and the utilization rate of the medicinal ingredients increases. However, gel-form preparations have the disadvantage that they cannot be sprayed well with a general sprayer. Therefore, the preparation before application is liquid, and the preparation that gels after application is preferable.
従来、持続性の高い粘膜適用液剤を提供するために、ポリビニルアルコール（ＰＶＡ）及びホウ酸を配合し眼中でゲル化する点眼剤（特許文献１参照）、涙液中のイオンによってゲル化するジェランガムを配合した点眼剤（特許文献２及び３参照）、フマル酸ケトチフェン及びカチオン応答型高分子を配合しｐＨが３〜６の点鼻組成物が開示されている（特許文献４参照）。
Conventionally, in order to provide a long-lasting mucosa-applied solution, an ophthalmic solution containing polyvinyl alcohol (PVA) and boric acid and gelled in the eye (see Patent Document 1), gellan gum gelled by ions in tear fluid An eye drop composition (see
また、従来ポリエチレングリコールとジェランガムを配合した外用剤は多数知られている（特許文献５〜１０参照）。しかしながら、水系溶媒にカチオン応答型高分子及びポリエチレングリコールを配合した粘膜適用液剤は知られておらず、ジェランガムのゲル化力の低下防止にポリエチレングリコールを配合することは知られていない。 Moreover, many external preparations which conventionally blended polyethylene glycol and gellan gum are known (see Patent Documents 5 to 10). However, there is no known mucosa-applied solution containing a cation-responsive polymer and polyethylene glycol in an aqueous solvent, and it is not known to add polyethylene glycol to prevent the gelling gum from lowering in gelling power.
さらに、ジェランガム及びポリエチレングリコールは眼表面上で液体-ゲル相転移を起こす基剤として知られている（特許文献１１参照）。 Furthermore, gellan gum and polyethylene glycol are known as bases that cause a liquid-gel phase transition on the ocular surface (see Patent Document 11).
本発明者らは、薬剤の効果を持続的に有する粘膜適用液剤を提供するために、カチオン応答型高分子を配合した粘膜適用液剤の提供を試みた。しかし、塗布時の刺激が少ない弱酸性領域では、製剤を保存することにより、付着性が低下してしまい、薬剤の効果を持続的に有する粘膜適用液剤が提供できないことがわかった。 The present inventors tried to provide a mucosa-applied solution containing a cation-responsive polymer in order to provide a mucosa-applied solution that has a drug effect continuously. However, it was found that, in a weakly acidic region where there is little irritation at the time of application, the adhesiveness is lowered by storing the preparation, and it is not possible to provide a mucosa-applied solution having a continuous drug effect.
本発明は、薬剤の効果を持続的に有する粘膜適用液剤を提供するために、カチオン応答型高分子による付着性の経時的な低下を抑制もしくは軽減した粘膜適用液剤を提供することを課題とする。 It is an object of the present invention to provide a mucosa-applied liquid agent that suppresses or reduces a decrease in adhesion over time due to a cation-responsive polymer in order to provide a mucosa-applied liquid agent that has a drug effect continuously. .
本発明者らは前記課題を解決するために鋭意検討を重ねた結果、カチオン応答型高分子であるジェランガム及びペクチンから選ばれる少なくとも１種を含有する水溶液に、ポリエチレングリコールを酸性領域で配合することにより、経時的な付着性の低下が抑制もしくは軽減できることを見出し、本発明を完成した。 As a result of intensive studies in order to solve the above problems, the present inventors have formulated polyethylene glycol in an acidic region in an aqueous solution containing at least one selected from gellan gum and pectin, which are cation-responsive polymers. Thus, it was found that the decrease in adhesion over time can be suppressed or reduced, and the present invention has been completed.
すなわち本発明は、
（１）水系溶媒にカチオン応答型高分子及びポリエチレングリコールを配合したことを特徴とする粘膜適用液剤、
（２）カチオン応答型高分子がジェランガム及びペクチンから選ばれる少なくとも１種である（１）記載の粘膜適用液剤、
（３）カチオン応答型高分子の配合量が粘膜適用液剤全体の０．０５w/v％〜１．２w/v％である（１）記載の粘膜適用液剤、
（４）ポリエチレングリコールの配合量が粘膜適用液剤全体の０．５w/v％〜１５w/v％である（１）〜（３）のいずれか１項に記載の粘膜適用液剤、
（５）ｐＨが３．５〜６．５である（１）〜（４）のいずれかに記載の粘膜適用液剤、
（６）点鼻剤又は点眼剤である（１）〜（５）のいずれかに記載の粘膜適用液剤、
（７）ポリエチレングリコールを配合することを特徴とする水系溶媒中でのカチオン応答型高分子の経時的なゲル化力の低下抑制方法、
である。
That is, the present invention
(1) A mucosa-applied solution characterized by containing a cation-responsive polymer and polyethylene glycol in an aqueous solvent,
(2) The liquid agent for mucosa according to (1), wherein the cation-responsive polymer is at least one selected from gellan gum and pectin,
(3) The mucosa-applied solution according to (1), wherein the amount of the cation-responsive polymer is 0.05 w / v% to 1.2 w / v% of the entire mucosa-applied solution,
(4) The mucosa-applied liquid according to any one of (1) to (3), wherein the blending amount of polyethylene glycol is 0.5 w / v% to 15 w / v% of the entire mucosa-applied liquid,
(5) The mucosa-applied solution according to any one of (1) to (4), having a pH of 3.5 to 6.5,
(6) The mucosa-applied solution according to any one of (1) to (5), which is a nasal drop or an eye drop,
(7) A method for suppressing a decrease in gelling power over time of a cation-responsive polymer in an aqueous solvent, comprising blending polyethylene glycol,
It is.
本発明の粘膜適用液剤は、投与前には噴霧等の塗布がしやすい液体で、粘膜部位に投与した際にゲル化することにより持続的な効果が得られ、経時的なゲル化力の低下はなかった。 The liquid preparation for mucosa of the present invention is a liquid that can be easily applied by spraying or the like before administration, and a continuous effect can be obtained by gelling when administered to a mucosal site, and the gelling power decreases with time. There was no.
本発明で用いるカチオン応答型高分子としては、一般的に医薬品に用いられるジェランガム及びペクチンを挙げることができる。 Examples of the cation-responsive polymer used in the present invention include gellan gum and pectin, which are generally used for pharmaceuticals.
本発明で用いるカチオン応答型高分子の好ましい配合量は粘膜適用液剤全体の０．０５〜１．２w/v％であり、さらに好ましい範囲は０．１〜０．６w/v％である。なお、カチオン応答型高分子は２種以上を組み合わせて用いることもできる。 A preferable blending amount of the cation-responsive polymer used in the present invention is 0.05 to 1.2 w / v% of the whole mucosa-applied solution, and a more preferable range is 0.1 to 0.6 w / v%. In addition, two or more kinds of cation-responsive polymers can be used in combination.
本発明において使用するポリエチレングリコール(以下、適宜ＰＥＧと表記する)は、エチレンオキシドと水との付加重合体である。重合度により液状から固体状のものまで存在し、医薬品等の基剤として汎用されている。本発明では、分子量が４００から６０００のＰＥＧが好ましい。本発明で、ＰＥＧの好ましい配合量は、粘膜適用液剤全体の０．５〜１５w/v％であり、さらに好ましい範囲は１〜５w/v％である。なお、ＰＥＧは複数の重合度のものを組み合わせて使用することもできる。 The polyethylene glycol used in the present invention (hereinafter referred to as PEG as appropriate) is an addition polymer of ethylene oxide and water. It exists from liquid to solid depending on the degree of polymerization, and is widely used as a base for pharmaceuticals. In the present invention, PEG having a molecular weight of 400 to 6000 is preferred. In the present invention, the preferred blending amount of PEG is 0.5 to 15 w / v% of the whole mucosa-applied solution, and a more preferred range is 1 to 5 w / v%. In addition, PEG can also be used combining the thing of several polymerization degree.
本発明の粘膜適用液剤のｐＨは、皮膚又は粘膜への刺激を最小限にするために、弱酸性のｐＨ３．５〜６．５が好ましく、より好ましくはｐＨ４〜６である。ｐＨが３．５未満であると皮膚や粘膜に刺激が生じる可能性がある。特に目や鼻の粘膜へ投与する際には、より刺激の少ないｐＨ４．５〜５．５であることが特に好ましい。 The pH of the liquid preparation for mucosa of the present invention is preferably weakly acidic pH 3.5 to 6.5, more preferably pH 4 to 6 in order to minimize irritation to the skin or mucous membrane. If the pH is less than 3.5, irritation may occur in the skin and mucous membrane. Particularly, when administered to the mucous membrane of the eyes and nose, it is particularly preferable that the pH is 4.5 to 5.5 with less irritation.
本発明で水系溶媒とは、水を主成分とする溶媒であり、点眼剤、点鼻剤などの粘膜適用液剤に使われる溶媒である。 In the present invention, the aqueous solvent is a solvent containing water as a main component, and is a solvent used for mucosa-applied solutions such as eye drops and nasal drops.
本発明の粘膜適用液剤は本発明の効果を損なわない範囲で、他の有効成分及び医薬品に含有可能な種々の添加物を配合することができる。 The mucosa-applied solution of the present invention can be blended with other active ingredients and various additives that can be contained in pharmaceuticals as long as the effects of the present invention are not impaired.
有効成分として例えば、ステロイド剤、殺菌剤、抗炎症剤、抗ヒスタミン剤、局所麻酔剤、収斂剤、血管収縮剤、抗アレルギー剤、清涼化剤、ビタミン、アミノ酸、ピント調節剤があげられる。 Examples of the active ingredient include steroids, bactericides, anti-inflammatory agents, antihistamines, local anesthetics, astringents, vasoconstrictors, antiallergic agents, cooling agents, vitamins, amino acids, and focus regulators.
また添加物として、精製水や低級アルコールなどの溶剤、安定化剤、界面活性剤、清涼化剤、増粘剤、緩衝剤、等張化剤、防腐剤、ｐＨ調節剤、抗酸化剤、香料、色素などを配合することができる。 Additives include solvents such as purified water and lower alcohols, stabilizers, surfactants, cooling agents, thickeners, buffers, isotonic agents, preservatives, pH regulators, antioxidants, perfumes. , Pigments and the like can be blended.
本発明の粘膜適用液剤は、精製水にカチオン応答型高分子を溶解した溶液に、フマル酸ケトチフェンなどの薬物及びポリエチレングリコールを各々精製水にて溶解した溶液を、攪拌下で添加することにより製造することができる。 The liquid preparation for mucosa of the present invention is produced by adding a solution in which a drug such as ketotifen fumarate and polyethylene glycol are dissolved in purified water to a solution in which the cation-responsive polymer is dissolved in purified water, with stirring. can do.
本発明の粘膜適用液剤は一般的な粘膜適用液剤の剤型で用いることができるが、高い付着性などの効果の点から粘膜適用製剤として用いるのが好ましい。粘膜適用製剤としては点眼剤、点鼻剤、口腔用剤、咽頭用剤、痔疾用剤などがあるが、点眼剤又は点鼻剤として用いることが特に好ましい。 The mucosa-applied solution of the present invention can be used in the form of a general mucosa-applied solution, but is preferably used as a mucosa-applied preparation in terms of effects such as high adhesion. Mucosal preparations include eye drops, nasal drops, oral preparations, pharyngeal preparations, hemorrhoid preparations, and the like, and particularly preferably used as eye drops or nasal drops.
以下、本発明を実施例及び試験例によりさらに詳細に説明する。 Hereinafter, the present invention will be described in more detail with reference to examples and test examples.
点鼻剤：
フマル酸ケトチフェン ０．０７５６g
塩酸ナファゾリン ０．０５g
ジェランガム ０．２g
ポリエチレングリコール４００ １g
EDTA-２Na ０．０５g
クエン酸 適量
クエン酸ナトリウム 適量
ジェランガム及びクエン酸ナトリウムを９０℃で加温溶解した後、室温まで冷却した。次いでその他の成分を溶解し、クエン酸-クエン酸ナトリウム緩衝液中でｐＨを４．５に調整し、精製水にて全量を１００mLとした。
Nasal drops:
Ketotifen fumarate 0.0756 g
Naphazoline hydrochloride 0.05g
Gellan gum 0.2g
Polyethylene glycol 400 1g
EDTA-2Na 0.05g
Citric acid appropriate amount Sodium citrate appropriate amount Gellan gum and sodium citrate were dissolved by heating at 90 ° C., and then cooled to room temperature. Next, the other components were dissolved, the pH was adjusted to 4.5 in a citric acid-sodium citrate buffer, and the total volume was adjusted to 100 mL with purified water.
点鼻剤：
フマル酸ケトチフェン ０．０７５６g
ペクチン １．２g
ポリエチレングリコール４００ ２．５g
EDTA-２Na ０．０５g
クエン酸 適量
クエン酸ナトリウム 適量
上記の各種成分を精製水に溶解させた後、クエン酸-クエン酸ナトリウム緩衝液にてｐＨを４．０に調整し、精製水にて全量を１００mLとした。
Nasal drops:
Ketotifen fumarate 0.0756 g
Pectin 1.2g
Polyethylene glycol 400 2.5g
EDTA-2Na 0.05g
Citric acid Appropriate amount Sodium citrate Appropriate amount After dissolving the above various components in purified water, the pH was adjusted to 4.0 with citric acid-sodium citrate buffer, and the total amount was adjusted to 100 mL with purified water.
点眼剤：
マレイン酸クロルフェニラミン ０．０３g
塩酸テトラヒドロゾリン ０．０５g
ジェランガム ０．４g
ポリエチレングリコール６０００ ０．５g
EDTA-２Na ０．０５g
クエン酸 適量
クエン酸ナトリウム 適量
塩化ベンザルコニウム ０．０１g
ポリソルベート８０ ０．１g
グリセリン 適量
上記の各種成分を精製水に溶解させた後、クエン酸-クエン酸ナトリウム緩衝液にてｐＨを５．５に調整し、精製水にて全量を１００mLとした。
Eye drops:
0.03 g chlorpheniramine maleate
Tetrahydrozoline hydrochloride 0.05g
Gellan gum 0.4g
Polyethylene glycol 6000 0.5g
EDTA-2Na 0.05g
Citric acid appropriate amount Sodium citrate appropriate amount Benzalkonium chloride 0.01g
Polysorbate 80 0.1g
Glycerin appropriate amount After dissolving the above various components in purified water, the pH was adjusted to 5.5 with a citric acid-sodium citrate buffer, and the total amount was adjusted to 100 mL with purified water.
実施例１又は３に準じて製造した実施例４〜２１及び比較例１〜４を下記表１−１〜１−３に示す。 Examples 4 to 21 and Comparative Examples 1 to 4 produced according to Example 1 or 3 are shown in the following Tables 1-1 to 1-3.
試験例１
実施例２、１７、比較例３及び４の点鼻剤を使用し、これを透明ガラス管に充填してサンプルとした。このサンプルの充填直後、６５℃にて１週間保存後及び２週間保存後のゲル化力を以下の方法で確認した。
Test example 1
The nasal drops of Examples 2 and 17 and Comparative Examples 3 and 4 were used and filled into a transparent glass tube to prepare a sample. Immediately after the filling of this sample, the gelling power after 1 week storage at 65 ° C. and after 2 weeks storage was confirmed by the following method.
下記表２に示す組成で佐分利らの報告(日本公衆衛生誌３９巻、６号、１９９２年「鼻汁によるスギ花粉の破裂」)を参考にして調製したｐＨ９．１のイオン溶液中にピペットを用いてサンプルを挿入して、１分間その形状を観察した後、その形状を判定し、ゲル化力を評価した。判定を容易にするため、各粘膜適用液剤に成分と相互作用のない色素（青色１号：ブリリアントブルーFCF：和光純薬製）を添加した。結果を図１及び２に示した。なお、評価基準は下記の通りである。
３：瞬時にゲルを形成し、１分後もゲルの形状に変化が見られなかった。
２：瞬時にゲルを形成したものの、１分後、ゲルの形状がわずかに崩れた。
１：瞬時にゲルを形成したものの、１分後、ゲルの形状は保持しなかった。
０：ゲルを形成しなかった。
Using a pipette in an ionic solution with a pH of 9.1 having the composition shown in Table 2 below and prepared by referring to the report by Toshi Sabe et al. After inserting the sample and observing its shape for 1 minute, the shape was judged and the gelling power was evaluated. In order to facilitate the determination, a dye that does not interact with the ingredients (Blue No. 1: Brilliant Blue FCF: manufactured by Wako Pure Chemical Industries, Ltd.) was added to each mucous membrane solution. The results are shown in FIGS. The evaluation criteria are as follows.
3: A gel was formed instantaneously, and no change was observed in the shape of the gel even after 1 minute.
2: Although a gel was instantly formed, the shape of the gel slightly collapsed after 1 minute.
1: Although a gel was formed instantaneously, the shape of the gel was not retained after 1 minute.
0: No gel was formed.
試験例２
実施例１、４〜９、１１、比較例１及び２の点鼻剤を使用し、これを透明ガラス管に充填してサンプルとした。このサンプルの充填直後、４０℃にて３ヶ月保存後及び６ヶ月保存後のゲル化力を以下の方法で確認した。
Test example 2
The nasal drops of Examples 1, 4 to 9, 11 and Comparative Examples 1 and 2 were used and filled into a transparent glass tube to prepare a sample. Immediately after the filling of this sample, the gelling power after storage for 3 months and after storage for 6 months at 40 ° C. was confirmed by the following method.
イオン溶液中に浸漬したセルロース膜（直径１４cm）を４５°の角度で平板に設置した。ファイファー社の噴霧量５０μLの点鼻用定量ポンプスプレーに各サンプルを充填し、膜に対して９０°の角度で各サンプルを２cmの距離から１回噴霧し、１分後セルロース膜上の液だれ距離を測定した。その結果を図３及び図４に示した。 A cellulose membrane (14 cm in diameter) immersed in an ionic solution was placed on a flat plate at an angle of 45 °. Each sample was filled in a 50 μL sprayed nasal metering pump spray from Pfeiffer, and each sample was sprayed once from a distance of 2 cm at an angle of 90 ° with respect to the membrane. The distance was measured. The results are shown in FIG. 3 and FIG.
本発明の実施例は、６ヶ月保存後も液だれ距離に大きな変化を認められず、ゲル化力が維持されることが判明した。一方、比較例は６ヶ月保存後では液だれ距離が約１０cmと長くなり、経時的にゲル化力が低下し、ゲルを形成しなくなることが示された。 In the examples of the present invention, it was found that the dripping distance was not significantly changed even after storage for 6 months, and the gelling power was maintained. On the other hand, in the comparative example, after the storage for 6 months, the dripping distance was as long as about 10 cm, and the gelling power decreased with time, indicating that no gel was formed.
試験例３
実施例２２、２３、比較例５〜７の液剤を表３の処方で製造した。各液剤を５０℃で１ヶ月及び２ヶ月保存し、５℃で保存したサンプルと試験例２と同様の方法でゲル化力を比較した。結果を図５及び６に示した。
Test example 3
The solutions of Examples 22 and 23 and Comparative Examples 5 to 7 were produced according to the formulations shown in Table 3. Each solution was stored at 50 ° C. for 1 month and 2 months, and the gelation power was compared with the sample stored at 5 ° C. in the same manner as in Test Example 2. The results are shown in FIGS.
本発明は、カチオン応答型高分子を配合する粘膜適用液剤の酸性域での経時的な付着性の低下を抑制することができるため、粘膜適用製剤として用いることができる。粘膜適用製剤としては具体的には、点眼剤、点鼻剤、口腔用剤、咽頭用剤、痔疾用剤などがあり、特に点眼剤又は点鼻剤として好適に用いることができる。 INDUSTRIAL APPLICABILITY The present invention can be used as a mucosa-applied preparation because it can suppress a decrease in adhesiveness over time in an acidic region of a mucosa-applied liquid formulation containing a cation-responsive polymer. Specific examples of the mucosa-applied preparation include eye drops, nasal drops, oral preparations, pharyngeal preparations, hemorrhoid preparations, and the like, and they can be suitably used particularly as eye drops or nasal drops.
Claims (7)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2006320940A JP5200365B2 (en) | 2005-11-30 | 2006-11-29 | Mucosal fluid |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2005345289 | 2005-11-30 | ||
| JP2005345289 | 2005-11-30 | ||
| JP2006320940A JP5200365B2 (en) | 2005-11-30 | 2006-11-29 | Mucosal fluid |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007176932A true JP2007176932A (en) | 2007-07-12 |
| JP5200365B2 JP5200365B2 (en) | 2013-06-05 |
Family
ID=38302447
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006320940A Active JP5200365B2 (en) | 2005-11-30 | 2006-11-29 | Mucosal fluid |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP5200365B2 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008120795A (en) * | 2006-10-18 | 2008-05-29 | Taisho Pharmaceutical Co Ltd | Liquid formulation applicable to mucosa |
| JP2010132644A (en) * | 2008-10-27 | 2010-06-17 | Taisho Pharmaceutical Co Ltd | Ophthalmic agent containing ketotifen fumarate |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH083074A (en) * | 1994-06-21 | 1996-01-09 | Sunstar Inc | Liquid composition for mouth |
| JPH11255654A (en) * | 1998-01-09 | 1999-09-21 | Taisho Pharmaceut Co Ltd | Nasal composition |
| JP2001048807A (en) * | 1999-08-04 | 2001-02-20 | Wakamoto Pharmaceut Co Ltd | Pharmaceutical preparation formed by dissolving slightly soluble medicament in water |
| JP2004510809A (en) * | 2000-10-10 | 2004-04-08 | ファルマシア・アンド・アップジョン・カンパニー | Topical antibiotic composition for treating the eye |
| JP2004143162A (en) * | 2002-10-01 | 2004-05-20 | Taisho Pharmaceut Co Ltd | Nasal drip composition |
| WO2005002595A1 (en) * | 2003-07-03 | 2005-01-13 | Menicon Co., Ltd. | Ophthalmic composition |
-
2006
- 2006-11-29 JP JP2006320940A patent/JP5200365B2/en active Active
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH083074A (en) * | 1994-06-21 | 1996-01-09 | Sunstar Inc | Liquid composition for mouth |
| JPH11255654A (en) * | 1998-01-09 | 1999-09-21 | Taisho Pharmaceut Co Ltd | Nasal composition |
| JP2001048807A (en) * | 1999-08-04 | 2001-02-20 | Wakamoto Pharmaceut Co Ltd | Pharmaceutical preparation formed by dissolving slightly soluble medicament in water |
| JP2004510809A (en) * | 2000-10-10 | 2004-04-08 | ファルマシア・アンド・アップジョン・カンパニー | Topical antibiotic composition for treating the eye |
| JP2004143162A (en) * | 2002-10-01 | 2004-05-20 | Taisho Pharmaceut Co Ltd | Nasal drip composition |
| WO2005002595A1 (en) * | 2003-07-03 | 2005-01-13 | Menicon Co., Ltd. | Ophthalmic composition |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008120795A (en) * | 2006-10-18 | 2008-05-29 | Taisho Pharmaceutical Co Ltd | Liquid formulation applicable to mucosa |
| JP2010132644A (en) * | 2008-10-27 | 2010-06-17 | Taisho Pharmaceutical Co Ltd | Ophthalmic agent containing ketotifen fumarate |
Also Published As
| Publication number | Publication date |
|---|---|
| JP5200365B2 (en) | 2013-06-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5215739A (en) | Spray gel base and spray gel preparation using thereof | |
| US5158761A (en) | Spray gel base and spray gel preparation using thereof | |
| US11896566B2 (en) | Pharmaceutical formulations of naproxen for soft gel encapsulation and combinations thereof | |
| JP2002356420A (en) | Table aqueous liquid medicine | |
| KR20100031608A (en) | Aqueous composition | |
| JP2014111587A (en) | Allergy preventive agent for ophthalmology | |
| ES2697343T3 (en) | Gel formulation comprising analgesic and anesthetic agents | |
| JP5200365B2 (en) | Mucosal fluid | |
| JP6177594B2 (en) | Aqueous ophthalmic composition | |
| JP2005187407A (en) | Ophthalmic composition for allergic eye disease | |
| JPH0623094B2 (en) | Gel base for spraying and gel using the same | |
| TW520296B (en) | Water-soluble eye drop | |
| US10004683B2 (en) | Antimicrobial formulations | |
| JPH1029937A (en) | Pharmaceutical preparation of mefenamic acid aqueous solution | |
| JP5109282B2 (en) | Liquid for external use | |
| JP2003095924A (en) | Heat gelling artificial lacrima | |
| JP2003055193A (en) | Refrigerant-containing gel-like external preparation | |
| JP2006348055A (en) | Alginic acid-containing composition | |
| JP2003055201A (en) | Solubilized composition containing vitamin a compounds and method for stabilizing vitamin a compounds | |
| JP2005008596A (en) | Ophthalmological composition | |
| JP2004143162A (en) | Nasal drip composition | |
| JP4771044B2 (en) | Mucosal fluid | |
| JP2007277233A (en) | Ophthalmic composition | |
| JP2008120795A (en) | Liquid formulation applicable to mucosa | |
| JP5533944B2 (en) | Liquid for external use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RD07 | Notification of extinguishment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7427 Effective date: 20090624 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20091124 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120417 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20120419 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120608 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120821 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20121016 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20130115 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20130128 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5200365 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20160222 Year of fee payment: 3 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20160222 Year of fee payment: 3 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |